ArticleFrontiers in microbiology2017
Virulence and Genomic Feature of a Virulent
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Klebsiella pneumoniae: an increasing threat to public health.Annals of clinical microbiology and antimicrobials · 2020Pooled it
- Genomic and functional characterization of ST11-KL64 hypervirulence-associated carbapenem-resistantFrontiers in microbiology · 2026Article
- Genome Characterization of Carbapenem-Resistant HypervirulentMicroorganisms · 2025Article
- Dissemination ofMicrobiology spectrum · 2025Article
- Shift in the dominant sequence type of carbapenem-resistant Klebsiella pneumonia infection from ST278-NDM-1 to ST11-KPC-2 in neonatal patients in a children's hospital in Shanghai, China, 2017-2021.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Genomic insights into the evolution and mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae co-harboring blaAnnals of clinical microbiology and antimicrobials · 2024Article
- Article
- Analysis of the hypovirulentMicrobiology spectrum · 2024Article
- Whole genome-based genetic insights ofMicrobiology spectrum · 2023Article
- Virulence factors in carbapenem-resistant hypervirulentFrontiers in microbiology · 2023Review
- Molecular epidemiology and clinical characteristics of the type VI secretion system inFrontiers in microbiology · 2023Article
- Genomic Epidemiology Insights on NDM-Producing Pathogens Revealed the Pivotal Role of Plasmids onMicrobiology spectrum · 2022Article
- Whole-Genomic Analysis of NDM-5-Producing Enterobacteriaceae Recovered from an Urban River in China.Infection and drug resistance · 2021Article
- Epigenomics, genomics, resistome, mobilome, virulome and evolutionary phylogenomics of carbapenem-resistantMicrobial genomics · 2020Article
- 3-in-1: bilateral subcutaneous leg abscesses and liver abscess fromBMJ case reports · 2020Article
- Outbreak of KPC-2 Carbapenem-resistant Klebsiella pneumoniae ST76 and Carbapenem-resistant K2 Hypervirulent Klebsiella pneumoniae ST375 strains in Northeast China: molecular and virulent characteristics.BMC infectious diseases · 2020Article
- Multiple NDM-5-ExpressingOpen forum infectious diseases · 2020Article
- Co-introduction of plasmids harbouring the carbapenemase genes, blaJournal of biomedical science · 2020Article
- Clonal dissemination of KPC-2-producingAnnals of translational medicine · 2019Article
- Hypervirulent Klebsiella pneumoniae.Clinical microbiology reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to reveal the molecular mechanism involved in carbapenem resistance and virulence of a K2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.